SCHEMBL1748987

SCHEMBL1748987

CNC1CCn2c(nc(C(=O)NCc3ccc(F)cc3)c(O)c2=O)C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.54
CYP2C9 P11712 1/20 0.54
MAPT P10636 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.44
KCNE1 P15382 1/20 0.43
CCR1 P32246 1/20 0.43
KCNQ1 P51787 1/20 0.43
LIPG Q9Y5X9 1/20 0.42
CALCA P06881 1/20 0.42
NPSR1 Q6W5P4 2/20 0.41
GAA P10253 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
LMNA P02545 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
ERCC1 P07992 1/20 0.41
FEN1 P39748 1/20 0.41
ERCC4 Q92889 1/20 0.41
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1375850 0.86 KCNH2 (0.58) KCNH2CYP2C9MAPTSMN1; SMN2KCNE1
SCHEMBL1376866 0.83 CYP2C9 (0.57) KCNH2CYP2C9MAPTSMN1; SMN2KCNE1
SCHEMBL1749463 0.83 KCNH2 (0.55) KCNH2CYP2C9MAPTSMN1; SMN2KCNE1
SCHEMBL87844 0.82 KCNH2 (0.52) KCNH2CYP2C9MAPTSMN1; SMN2KCNE1
SCHEMBL1750602 0.81 MAPT (0.63) KCNH2CYP2C9MAPTCALCAGAA
SCHEMBL1376535 0.81 MAPT (0.61) KCNH2CYP2C9MAPTCALCAGAA
SCHEMBL2208272 0.80 KCNH2 (0.53) KCNH2CYP2C9MAPTSMN1; SMN2KCNE1
SCHEMBL87322 0.80 KCNH2 (0.51) KCNH2CYP2C9MAPTSMN1; SMN2KCNE1
SCHEMBL13691708 0.80 KCNH2 (0.51) KCNH2CYP2C9MAPTSMN1; SMN2KCNE1
SCHEMBL1376994 0.80 MAPT (0.60) KCNH2CYP2C9MAPTCALCAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968553-B2 e.g. N-(4-fluorobenzyl)-3-hydroxy-4-oxo-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidine-2-carboxamide; viricide in combination with other HIV/AIDS antivirals, immunomodulators, antibiotics or vaccines; AIDS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2011-06-28 US disclosed
US-7414045-B2 Substituted pyrimido[1,2-a]azepines useful as HIV integrase inhibitors ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2008-08-19 US disclosed
US-20080176869-A1 Tetrahydro-4H-pyrido[1,2-a] pyrimidines useful as HIV integrase inhibitors MSD ITALIA S.R.L. (IT) 2008-07-24 US disclosed
US-20060046985-A1 Tetrahydro--4h-pyrido[1,2-a}pyrimidines and related compounds useful as hiv integrase inhibitors MSD ITALIA S.R.L. (IT) 2006-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060046985-A1 Tetrahydro--4h-pyrido[1,2-a}pyrimidines and related compounds useful as hiv integrase inhibitors TYMS, TYMP, HPRT1 KCNH2 3284/4885CYP2C9 754/4885MAPT 1213/4885
US-20080176869-A1 Tetrahydro-4H-pyrido[1,2-a] pyrimidines useful as HIV integrase inhibitors TYMS, TYMP, DPYD KCNH2 3301/4885CYP2C9 740/4885MAPT 1773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.